Takeda Pharmaceutical Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Takeda Pharmaceutical ha un patrimonio netto totale di ¥6,921.6B e un debito totale di ¥5,051.2B, che porta il suo rapporto debito/patrimonio netto a 73%. Le sue attività totali e le sue passività totali sono rispettivamente ¥14,573.0B e ¥7,651.4B. L'EBIT di Takeda Pharmaceutical è ¥653.6B rendendo il suo rapporto di copertura degli interessi 6.7. Ha liquidità e investimenti a breve termine pari a ¥859.0B.

Informazioni chiave

73.0%

Rapporto debito/patrimonio netto

JP¥5.05t

Debito

Indice di copertura degli interessi	6.7x
Contanti	JP¥859.02b
Patrimonio netto	JP¥6.92t
Totale passività	JP¥7.65t
Totale attività	JP¥14.57t

Aggiornamenti recenti sulla salute finanziaria

Takeda Pharmaceutical (TSE:4502) Takes On Some Risk With Its Use Of Debt

Jun 11

Recent updates

Results: Takeda Pharmaceutical Company Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Nov 04

Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00

Sep 24

Why Investors Shouldn't Be Surprised By Takeda Pharmaceutical Company Limited's (TSE:4502) P/E

Sep 20

Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's

Aug 08

Earnings Beat: Takeda Pharmaceutical Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 02

Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00

Jul 25

Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's

Jul 11

Takeda Pharmaceutical Company Limited (TSE:4502) Yearly Results: Here's What Analysts Are Forecasting For This Year

Jun 30

Takeda Pharmaceutical (TSE:4502) Takes On Some Risk With Its Use Of Debt

Jun 11

Some Investors May Be Willing To Look Past Takeda Pharmaceutical's (TSE:4502) Soft Earnings

May 21

Takeda Pharmaceutical Company Limited Just Recorded A 6.0% EPS Beat: Here's What Analysts Are Forecasting Next

May 12

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( ¥3,054.0B ) di 4502 superano le sue passività a breve termine ( ¥2,387.2B ).

Passività a lungo termine: Le attività a breve termine di 4502 ( ¥3,054.0B ) non coprono le sue passività a lungo termine ( ¥5,264.2B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 60.6% ) di 4502 è considerato alto.

Riduzione del debito: Il rapporto debito/patrimonio netto di 4502 si è ridotto da 103.2% a 73% negli ultimi 5 anni.

Copertura del debito: Il debito di 4502 non è ben coperto dal flusso di cassa operativo ( 17.3% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di 4502 sono ben coperti dall'EBIT ( 6.7 x copertura).

Takeda Pharmaceutical Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Takeda Pharmaceutical (TSE:4502) Takes On Some Risk With Its Use Of Debt

Recent updates

Results: Takeda Pharmaceutical Company Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Takeda Pharmaceutical Company Limited Raises Earnings Guidance for the Full Year 2024

Takeda Receives Approval from the Japanese Ministry of Health, Labour and Welfare to Manufacture and Market Fruquintinib for Previously Treated Colorectal Cancer

Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00

Why Investors Shouldn't Be Surprised By Takeda Pharmaceutical Company Limited's (TSE:4502) P/E

Upcoming dividend of JP¥98.00 per share

Consensus EPS estimates increase by 13%

Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's

Takeda Receives European Commission Approval for ADZYNMA®

Earnings Beat: Takeda Pharmaceutical Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00

Consensus EPS estimates fall by 17%

Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's

Final dividend of JP¥98.00 announced

Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited (TSE:4502) Yearly Results: Here's What Analysts Are Forecasting For This Year

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)

Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Consensus EPS estimates fall by 18%

Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda Pharmaceutical (TSE:4502) Takes On Some Risk With Its Use Of Debt

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Consensus EPS estimates fall by 11%

Some Investors May Be Willing To Look Past Takeda Pharmaceutical's (TSE:4502) Soft Earnings

Takeda Pharmaceutical Company Limited Just Recorded A 6.0% EPS Beat: Here's What Analysts Are Forecasting Next

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical (TSE:4502) Is Due To Pay A Dividend Of ¥94.00

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Upcoming dividend of JP¥94.00 per share

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Pharmaceutical (TSE:4502) Has Announced A Dividend Of ¥94.00

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

Takeda Pharmaceutical (TSE:4502) Will Pay A Dividend Of ¥94.00

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda's Gammard Liquidid®? Approves by U.S. Fda for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Takeda Announces U.S. Food and Drug Administration Approves Hyqvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Takeda Pharmaceutical Company Limited to Report Q2, 2025 Results on Oct 31, 2024

Takeda Receives Positive Chmp Opinion for Hyqvia as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Consensus EPS estimates increase by 13%

Consensus EPS estimates fall by 24%

The European Commission Approves Label Update for Takhzyro®? (Lanadelumab), Expanding Its Use to A Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (Hae)

U.S. Fda Approves Takeda's Adzynma (Adamts13, Recombinant-Krhn) as the First and Only Recombinant Adamts13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombotic Thrombocytopenic Purpura

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Takeda Pharmaceutical Company Limited Announces Late-Breaking Data from Phase 2B Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis At American College of Rheumatology Convergence Annual Meeting

Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Year-End Dividend Guidance for the Year Ending March 31, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Takeda Pharmaceutical Company Limited Announces European Commission Approves ADCETRIS (Brentuximab Vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study

Takeda Pharmaceutical Company Limited to Report Q3, 2024 Results on Feb 01, 2024

Takeda Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema in Patients Aged 2 Years and Older

Takeda Announces FDA Acceptance of NDA Resubmission of Tak-721 (Budesonide Oral Suspension) for the Short-Term Treatment of Eosinophilic Esophagitis

Upcoming dividend of JP¥94.00 per share at 4.0% yield

Takeda Pharmaceutical Company Limited Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a highly selective oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

New minor risk - Earnings quality